In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cumberland Pharmaceuticals Inc.

www.cumberlandpharma.com

Latest From Cumberland Pharmaceuticals Inc.

Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate

Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.

Deals Business Strategies

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies

Opioid-Sparing Claims Should Meet High Bar, US FDA Panel Says

At meeting on Pacira's Exparel, advisory committee members warn against rushing to adopt products purported to reduce opioid consumption absent long-term longitudinal data showing beneficial public health impacts and clinical data linking reduced opioid use to functional outcomes or other clinical benefit.

Advisory Committees Drug Approval Standards

New MOA For Schizophrenia Treatment Sought In Lundbeck / Vanderbilt Pact

The Danish CNS specialist has entered into a pact with Vanderbilt University to jointly develop a new way to treat schizophrenia.

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Poison (Antidote)
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cumberland Pharmaceuticals Inc.
  • Senior Management
  • A.J. Kazimi, Chmn. & CEO
    Michael Bonner, CFO
    Martin E Cearnal, EVP, Chief Commercial Officer
    Leo Pavliv, SVP, Operations & Chief Dev. Officer
  • Contact Info
  • Cumberland Pharmaceuticals Inc.
    Phone: (615) 255-0068
    2525 W. End Ave., Ste. 950
    Nashville, TN 37203
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register